Gilead Sciences' Trodelvy lowered the risk of disease progression in an aggressive type of breast cancer by 38% when used as ...
Shares of Gilead Sciences Inc. rose 4.21% to $122.81 Friday, on what proved to be an all-around great trading session for the ...
Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its antiviral research and development programs at IDWeek ...
The biopharma will aim to bolster its pipeline, with plans to present updated results for novel long-acting combination ...
Discover why Gilead Sciences (GILD) is a top healthcare stock in 2025 with strong fundamentals and growth potential.
1d
A Look at Gilead Sciences’s Valuation Following Breakthrough HIV and Cancer Clinical Trial Results
Gilead Sciences (GILD) is drawing attention this week as it presents new clinical results at both the European AIDS ...
In the first opportunity for industry watchers to compare the two approved TROP2 antibody-drug conjugates side by side in ...
AstraZeneca and Gilead both reported successful trials in a hard-to-treat form of breast cancer, sparking a debate about ...
Gilead Sciences Inc. (GILD) reached a notable milestone as its stock hit a 52-week high of $121.84, with InvestingPro data ...
Late-Breaking ASCENT-03 Data Simultaneously Presented at ESMO 2025 and Published in The New England Journal of Medicine - - With Two Positive Phase 3 Trials, Trodelvy Has Potential as the First ...
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $125.0, along ...
Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback